These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36379903)
21. Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management. Tepes B; Brglez Jurecic N; Tepes K; Espada Sanchez M; Perez Nyssen O; O'Morain C; Mégraud F; Gisbert J Dig Dis; 2021; 39(4):318-324. PubMed ID: 33099549 [TBL] [Abstract][Full Text] [Related]
22. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gisbert JP; Alcedo J; Amador J; Bujanda L; Calvet X; Castro-Fernández M; Fernández-Salazar L; Gené E; Lanas Á; Lucendo AJ; Molina-Infante J; Nyssen OP; Pérez-Aisa A; Puig I Gastroenterol Hepatol; 2022 May; 45(5):392-417. PubMed ID: 34629204 [TBL] [Abstract][Full Text] [Related]
23. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. Ergül B; Doğan Z; Sarikaya M; Filik L Helicobacter; 2013 Dec; 18(6):454-8. PubMed ID: 24011287 [TBL] [Abstract][Full Text] [Related]
25. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551 [TBL] [Abstract][Full Text] [Related]
26. Evidence-based recommendations for successful Helicobacter pylori treatment. Wu JY; Liou JM; Graham DY Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):21-8. PubMed ID: 24410470 [TBL] [Abstract][Full Text] [Related]
27. Tailored eradication Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776 [TBL] [Abstract][Full Text] [Related]
28. Recent Developments Pertaining to H. pylori Infection. Howden CW; Graham DY Am J Gastroenterol; 2021 Jan; 116(1):1-3. PubMed ID: 33378314 [No Abstract] [Full Text] [Related]
31. Novel and Effective Therapeutic Regimens for Hu Y; Zhu Y; Lu NH Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929 [No Abstract] [Full Text] [Related]
32. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122 [TBL] [Abstract][Full Text] [Related]
33. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Gisbert JP; Gonzalez L; Calvet X Helicobacter; 2005 Jun; 10(3):157-71. PubMed ID: 15904473 [TBL] [Abstract][Full Text] [Related]
34. Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Seo SI; Lim H; Bang CS; Yang YJ; Baik GH; Lee SP; Jang HJ; Kae SH; Kim J; Kim HY; Shin WG Gut Liver; 2022 Sep; 16(5):697-705. PubMed ID: 35145043 [TBL] [Abstract][Full Text] [Related]
35. [European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow]. Bordin DS; Voynovan IN; Embutnieks YV; Nyssen OP; Megraud F; O Morain C; Perez-Gisbert J Ter Arkh; 2020 Apr; 92(2):12-18. PubMed ID: 32598712 [TBL] [Abstract][Full Text] [Related]
36. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG; Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798 [TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Gisbert JP; González L; Calvet X; Roqué M; Gabriel R; Pajares JM Aliment Pharmacol Ther; 2000 Sep; 14(9):1141-50. PubMed ID: 10971230 [TBL] [Abstract][Full Text] [Related]
38. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]. Hinostroza Morales D; Díaz Ferrer J Rev Gastroenterol Peru; 2014; 34(4):315-20. PubMed ID: 25594755 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of azythromicin-based triple therapy for Helicobacter pylori infection: a retrospective study. Pellicano R; Astegiano M; Smedile A; Saracco G; Berrutti M; Morgando A; Fadda M; Repici A; Fagoonee S; Rizzetto M Panminerva Med; 2008 Sep; 50(3):259-60. PubMed ID: 18927531 [No Abstract] [Full Text] [Related]
40. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P Digestion; 2013; 88(1):33-45. PubMed ID: 23880479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]